Protocol Ledger

NCT06440993 · Phase II · RECRUITING

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma

Interventional Phase II clinical trial protocol NCT06440993 sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-23 Enrollment: 42 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06440993
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06440993
Protocol FieldVerified Registry Value
NCT IdentifierNCT06440993
Consolidated Lead SponsorInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment42 participants (ESTIMATED)
Registered Start Date2024-08-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06440993
Hospital Research SiteLocationSite Profile
Universitätsklinikum BonnBonn, GermanyOpen Hospital Dossier ->
Medizinische Hochschule HannoverHanover, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI